Skip to content
10-K

Annual Report

RECURSION PHARMACEUTICALS, INC. RXRX

0001601830-26-000039

← back to feed
Filed
Feb 25, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 447.45M sh
Shares Diluted FY 2025 · Dec 31, 2024 274.21M sh
Shares Diluted FY 2025 · Dec 31, 2023 207.85M sh
Capex FY 2025 · Dec 31, 2025 $6.47M
Capex FY 2025 · Dec 31, 2024 $13.7M
Capex FY 2025 · Dec 31, 2023 $11.96M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$371.81M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$359.17M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$287.78M
Cash And Equivalents FY 2025 · Dec 31, 2025 $743.29M
Cash And Equivalents FY 2025 · Dec 31, 2024 $594.35M
Stockholders Equity FY 2025 · Dec 31, 2025 $1.13B
Stockholders Equity FY 2025 · Dec 31, 2024 $1.03B
Stockholders Equity FY 2025 · Dec 31, 2023 $463.44M
Stockholders Equity FY 2025 · Dec 31, 2022 $485.81M
Current Liabilities FY 2025 · Dec 31, 2025 $147.71M
Current Liabilities FY 2025 · Dec 31, 2024 $187.47M
Total Liabilities FY 2025 · Dec 31, 2025 $343.27M
Total Liabilities FY 2025 · Dec 31, 2024 $413.82M
Current Assets FY 2025 · Dec 31, 2025 $812.85M
Current Assets FY 2025 · Dec 31, 2024 $714.27M
Total Assets FY 2025 · Dec 31, 2025 $1.47B
Total Assets FY 2025 · Dec 31, 2024 $1.45B
Eps Diluted FY 2025 · Dec 31, 2025 −$1.44
Eps Diluted FY 2025 · Dec 31, 2024 −$1.69
Eps Diluted FY 2025 · Dec 31, 2023 −$1.58
Eps Basic FY 2025 · Dec 31, 2025 −$1.44
Eps Basic FY 2025 · Dec 31, 2024 −$1.69
Eps Basic FY 2025 · Dec 31, 2023 −$1.58
Sga Expense FY 2025 · Dec 31, 2025 $176.59M
Sga Expense FY 2025 · Dec 31, 2024 $178.18M
Sga Expense FY 2025 · Dec 31, 2023 $110.82M
Rd Expense FY 2025 · Dec 31, 2025 $475.27M
Rd Expense FY 2025 · Dec 31, 2024 $314.42M
Rd Expense FY 2025 · Dec 31, 2023 $241.23M
Net Income FY 2025 · Dec 31, 2025 −$644.76M
Net Income FY 2025 · Dec 31, 2024 −$463.66M
Net Income FY 2025 · Dec 31, 2023 −$328.07M
Operating Income FY 2025 · Dec 31, 2025 −$648.13M
Operating Income FY 2025 · Dec 31, 2024 −$479M
Operating Income FY 2025 · Dec 31, 2023 −$350.06M
Cost Of Revenue FY 2025 · Dec 31, 2025 $70.95M
Cost Of Revenue FY 2025 · Dec 31, 2024 $45.24M
Cost Of Revenue FY 2025 · Dec 31, 2023 $42.59M
Revenue FY 2025 · Dec 31, 2025 $74.68M
Revenue FY 2025 · Dec 31, 2024 $58.84M
Revenue FY 2025 · Dec 31, 2023 $44.58M